OTCPK:SMHGF (China)
Â
Ordinary Shares
$
1.4894
(0%)
10:08 PM EST
Business Description
Simcere Pharmaceutical Group Ltd
ISIN : HK0000658531
Share Class Description:
SMHGF: Ordinary SharesTotal Employee Number:
7,038Compare
Compare
Traded in other countries / regions
02096.Hong KongS2P.GermanySMHGF.USA IPO Date
2020-10-28Description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.01 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | 0.74 | |||||
Interest Coverage | 14.56 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 4.56 | |||||
Beneish M-Score | -2.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.4 | |||||
3-Year EBITDA Growth Rate | 19.9 | |||||
3-Year EPS without NRI Growth Rate | 22.7 | |||||
3-Year FCF Growth Rate | 21.1 | |||||
3-Year Book Growth Rate | 10.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.43 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.35 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 0.26 | |||||
14-Day RSI | 3.29 | |||||
6-1 Month Momentum % | -24.01 | |||||
12-1 Month Momentum % | 115.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.21 | |||||
Quick Ratio | 2.03 | |||||
Cash Ratio | 1.07 | |||||
Days Inventory | 148.72 | |||||
Days Sales Outstanding | 112.32 | |||||
Days Payable | 60.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.31 | |||||
3-Year Dividend Growth Rate | 1.6 | |||||
3-Year Average Share Buyback Ratio | 0.8 | |||||
Shareholder Yield % | -3.12 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.62 | |||||
Operating Margin % | 18.03 | |||||
Net Margin % | 17.39 | |||||
EBITDA Margin % | 20.83 | |||||
FCF Margin % | 14.81 | |||||
OCF Margin % | 26.06 | |||||
ROE % | 17.11 | |||||
ROA % | 10.45 | |||||
ROIC % | 13.95 | |||||
3-Year ROIIC % | 26.94 | |||||
ROC (Joel Greenblatt) % | 46.03 | |||||
ROCE % | 16.62 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 21.47 | |||||
Forward PE Ratio | 15.85 | |||||
PE Ratio without NRI | 23.15 | |||||
Price-to-Owner-Earnings | 16.93 | |||||
PEG Ratio | 7.23 | |||||
PS Ratio | 3.73 | |||||
PB Ratio | 3.18 | |||||
Price-to-Tangible-Book | 3.82 | |||||
Price-to-Free-Cash-Flow | 24.91 | |||||
Price-to-Operating-Cash-Flow | 14.34 | |||||
EV-to-EBIT | 16.91 | |||||
EV-to-EBITDA | 16.91 | |||||
EV-to-Revenue | 3.52 | |||||
EV-to-FCF | 23.72 | |||||
Price-to-GF-Value | 1.18 | |||||
Price-to-Projected-FCF | 3.04 | |||||
Price-to-Graham-Number | 1.99 | |||||
| Price-to-Net-Current-Asset-Value | 14.89 | |||||
Earnings Yield (Greenblatt) % | 5.91 | |||||
FCF Yield % | 3.86 | |||||
Forward Rate of Return (Yacktman) % | 3.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SMHGF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Simcere Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,087.988 | ||
| EPS (TTM) ($) | 0.076 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 186.74 | ||
| 14-Day RSI | 3.29 | ||
| 14-Day ATR ($) | 0.000031 | ||
| 20-Day SMA ($) | 1.48945 | ||
| 12-1 Month Momentum % | 115.18 | ||
| 52-Week Range ($) | 0.6922 - 1.96 | ||
| Shares Outstanding (Mil) | 2,568.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Simcere Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Simcere Pharmaceutical Group Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| HKD 0.206900 Cash Dividend | 2026-06-17 | 1.49 (+0.00%) | ||
| HKD 0.174800 Cash Dividend | 2025-06-20 | 0.69 (+0.00%) |
Show
Entries
Simcere Pharmaceutical Group Ltd Frequently Asked Questions
What is Simcere Pharmaceutical Group Ltd(SMHGF)'s stock price today?
The current price of SMHGF is $1.49. The 52 week high of SMHGF is $1.96 and 52 week low is $0.69.
When is next earnings date of Simcere Pharmaceutical Group Ltd(SMHGF)?
The next earnings date of Simcere Pharmaceutical Group Ltd(SMHGF) is .
Does Simcere Pharmaceutical Group Ltd(SMHGF) pay dividends? If so, how much?
Simcere Pharmaceutical Group Ltd(SMHGF) does not pay dividend.
Guru Commentaries on OTCPK:SMHGF
No articles.
Press Release
Articles on Simcere Pharmaceutical Group Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers